The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
2025 Nobel Prize in Medicine Spotlights the Mechanism of Cancer Immune Evasion
By The Cancer News Team
The 2025 Nobel Prize in Medicine honors the discovery of FOXP3 and regulatory T cells, revealing how immune tolerance prevents autoimmunity and shapes cancer immune evasion.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
FDA approves Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated metastatic breast cancer
By Shipra Gandhi, MD, MS
The FDA has approved imlunestrant (Inluriyo), a new oral SERD, for treating ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, expanding targeted therapy options for patients with endocrine-resistant disease.
How One PhD Student Is Bridging Cervical Cancer Research and Community Impact
By The Cancer News Team
How one PhD student is bridging cervical cancer research and community outreach to improve prevention and treatment access in underserved regions of Nepal.
How One PhD Student Is Bridging Cervical Cancer Research and Community Impact
By The Cancer News Team
How one PhD student is bridging cervical cancer research and community outreach to improve prevention and treatment access in underserved regions of Nepal.
How One PhD Student Is Bridging Cervical Cancer Research and Community Impact
By The Cancer News Team
How one PhD student is bridging cervical cancer research and community outreach to improve prevention and treatment access in underserved regions of Nepal.
Meredith Pelster, MD, MSCI, on GI Malignancies—What is on the Horizon for Cellular Therapy?
By The Cancer News Team
Meredith Pelster, MD, MSCI, discusses the challenges and emerging opportunities of cellular therapy in GI malignancies, highlighting insights from the 2025 Seattle Cellular Therapy Summit.
Meredith Pelster, MD, MSCI, on GI Malignancies—What is on the Horizon for Cellular Therapy?
By The Cancer News Team
Meredith Pelster, MD, MSCI, discusses the challenges and emerging opportunities of cellular therapy in GI malignancies, highlighting insights from the 2025 Seattle Cellular Therapy Summit.
Meredith Pelster, MD, MSCI, on GI Malignancies—What is on the Horizon for Cellular Therapy?
By The Cancer News Team
Meredith Pelster, MD, MSCI, discusses the challenges and emerging opportunities of cellular therapy in GI malignancies, highlighting insights from the 2025 Seattle Cellular Therapy Summit.
Rosa Nadal Rios, MD, PhD, on GU Malignancies—What is on the Horizon for Cellular Therapy?
By The Cancer News Team
Rosa Nadal Rios, MD, PhD, shares insights on the future of cellular therapy in GU malignancies, highlighting advances in prostate, kidney, and testicular cancers at the 2025 Seattle Cellular Therapy Summit.
Rosa Nadal Rios, MD, PhD, on GU Malignancies—What is on the Horizon for Cellular Therapy?
By The Cancer News Team
Rosa Nadal Rios, MD, PhD, shares insights on the future of cellular therapy in GU malignancies, highlighting advances in prostate, kidney, and testicular cancers at the 2025 Seattle Cellular Therapy Summit.
Rosa Nadal Rios, MD, PhD, on GU Malignancies—What is on the Horizon for Cellular Therapy?
By The Cancer News Team
Rosa Nadal Rios, MD, PhD, shares insights on the future of cellular therapy in GU malignancies, highlighting advances in prostate, kidney, and testicular cancers at the 2025 Seattle Cellular Therapy Summit.
World Cancer Research Day 2025: Progress, Challenges, and What’s Next in U.S. Cancer Research
By Aishat Motolani, PhD
Explore the progress, challenges, and future directions of U.S. cancer research on World Cancer Research Day 2025, from immunotherapy and RNA vaccines to AI, prevention, and health equity.
World Cancer Research Day 2025: Progress, Challenges, and What’s Next in U.S. Cancer Research
By Aishat Motolani, PhD
Explore the progress, challenges, and future directions of U.S. cancer research on World Cancer Research Day 2025, from immunotherapy and RNA vaccines to AI, prevention, and health equity.
World Cancer Research Day 2025: Progress, Challenges, and What’s Next in U.S. Cancer Research
By Aishat Motolani, PhD
Explore the progress, challenges, and future directions of U.S. cancer research on World Cancer Research Day 2025, from immunotherapy and RNA vaccines to AI, prevention, and health equity.
GI Oncologist Discusses the Challenge of Translating CHALLENGE Trial Results into Patient Care
By The Cancer News Team
GI oncologist Dr. Ronan Hsieh discusses the CHALLENGE trial, exploring how exercise improves colon cancer survival and the barriers to implementing structured exercise programs in clinical practice.
GI Oncologist Discusses the Challenge of Translating CHALLENGE Trial Results into Patient Care
By The Cancer News Team
GI oncologist Dr. Ronan Hsieh discusses the CHALLENGE trial, exploring how exercise improves colon cancer survival and the barriers to implementing structured exercise programs in clinical practice.
GI Oncologist Discusses the Challenge of Translating CHALLENGE Trial Results into Patient Care
By The Cancer News Team
GI oncologist Dr. Ronan Hsieh discusses the CHALLENGE trial, exploring how exercise improves colon cancer survival and the barriers to implementing structured exercise programs in clinical practice.
What Cancer Doctors Are Saying About Ivermectin and Cancer Treatment
By The Cancer News Team
Oncologists explain why ivermectin is not a proven cancer treatment, summarizing current evidence, ongoing trials in TNBC, and how clinicians address patient misinformation.
What Cancer Doctors Are Saying About Ivermectin and Cancer Treatment
By The Cancer News Team
Oncologists explain why ivermectin is not a proven cancer treatment, summarizing current evidence, ongoing trials in TNBC, and how clinicians address patient misinformation.
What Cancer Doctors Are Saying About Ivermectin and Cancer Treatment
By The Cancer News Team
Oncologists explain why ivermectin is not a proven cancer treatment, summarizing current evidence, ongoing trials in TNBC, and how clinicians address patient misinformation.
New Biomarkers Predict Chemotherapy Resistance Across Multiple Cancer Types
By The Cancer News Team
New research identifies chromosomal instability (CIN) biomarkers that predict chemotherapy resistance across multiple cancer types, offering a breakthrough in precision oncology.
New Biomarkers Predict Chemotherapy Resistance Across Multiple Cancer Types
By The Cancer News Team
New research identifies chromosomal instability (CIN) biomarkers that predict chemotherapy resistance across multiple cancer types, offering a breakthrough in precision oncology.
New Biomarkers Predict Chemotherapy Resistance Across Multiple Cancer Types
By The Cancer News Team
New research identifies chromosomal instability (CIN) biomarkers that predict chemotherapy resistance across multiple cancer types, offering a breakthrough in precision oncology.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
By Prakash Ambady, MD
FDA grants accelerated approval to dordaviprone, the first systemic therapy for diffuse midline glioma with an H3 K27M mutation, offering new hope for patients after progression on prior treatment.